We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+16%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$2.62M
Cap. Flow
% of AUM
-0.81%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
243
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
+$3.29M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$1.96M |
| 3 |
Apple
AAPL
|
+$1.92M |
| 4 |
Vaxcyte
PCVX
|
+$1.9M |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iQIYI
IQ
|
+$5.11M |
| 2 |
Amazon
AMZN
|
+$4.12M |
| 3 |
Airbnb
ABNB
|
+$2.92M |
| 4 |
Analog Devices
ADI
|
+$2.79M |
| 5 |
KE Holdings
BEKE
|
+$2.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Edwards Lifesciences
EW
$53.6B
| $24.1K | 0.01% |
256
| – | – |
|
252
Pacira BioSciences
PCRX
$945M
| $24.1K | 0.01% |
602
-21
| -3% | -$868 |
|
|
BLU
253
DELISTED
BELLUS Health Inc.
BLU
| $24.1K | 0.01% |
1,634
-71
| -4% | -$943 |
|
254
Zscaler
ZS
$28.7B
| $24K | 0.01% |
164
+120
| +273% | +$14.7K |
|
255
Summit Therapeutics
SMMT
$12B
| $23K | 0.01% |
9,145
-308
| -3% | -$562 |
|
256
Zai Lab
ZLAB
$2.86B
| $22.6K | 0.01% |
814
-131
| -14% | -$4.29K |
|
257
Zentalis Pharmaceuticals
ZNTL
$307M
| $22K | 0.01% |
779
+6
| +0.8% | +$144 |
|
258
Genmab
GMAB
$19.6B
| $21.9K | 0.01% |
577
-55
| -9% | -$2.19K |
|
259
Ironwood Pharmaceuticals
IRWD
$714M
| $21.7K | 0.01% |
2,036
-53
| -3% | -$570 |
|
|
SWTX
260
DELISTED
SpringWorks Therapeutics
SWTX
| $21.5K | 0.01% |
820
-27
| -3% | -$710 |
|
261
Maravai LifeSciences
MRVI
$861M
| $21.5K | 0.01% |
1,729
-57
| -3% | -$769 |
|
262
Supernus Pharmaceuticals
SUPN
$2.78B
| $21.5K | 0.01% |
714
-19
| -3% | -$665 |
|
263
Geron
GERN
$1.01B
| $21.4K | 0.01% |
6,669
+747
| +13% | +$2.13K |
|
264
Rocket Pharmaceuticals
RCKT
$374M
| $20.9K | 0.01% |
1,054
-21
| -2% | -$424 |
|
265
Protagonist Therapeutics
PTGX
$9.84B
| $20.7K | 0.01% |
750
+83
| +12% | +$2.08K |
|
266
Iovance Biotherapeutics
IOVA
$3.05B
| $20.7K | 0.01% |
2,942
-96
| -3% | -$687 |
|
267
Agios Pharmaceuticals
AGIO
$2.04B
| $20.6K | 0.01% |
729
-20
| -3% | -$498 |
|
268
Relay Therapeutics
RLAY
$4.4B
| $20K | 0.01% |
1,594
-50
| -3% | -$622 |
|
|
ACLX
269
DELISTED
Arcellx
ACLX
| $19.9K | 0.01% |
629
+35
| +6% | +$1.34K |
|
270
Xencor
XNCR
$1.72B
| $19.8K | 0.01% |
792
-22
| -3% | -$599 |
|
271
SiriusXM
SIRI
$9.59B
| $19.8K | 0.01% |
437
+319
| +270% | +$12K |
|
272
Amylyx Pharmaceuticals
AMLX
$2.6B
| $19K | 0.01% |
880
-17
| -2% | -$459 |
|
273
IQVIA
IQV
$39.8B
| $18.9K | 0.01% |
84
| – | – |
|
274
Syndax Pharmaceuticals
SNDX
$1.77B
| $18.9K | 0.01% |
902
-26
| -3% | -$541 |
|
275
Charles River Laboratories
CRL
$13.6B
| $18.7K | 0.01% |
89
| – | – |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q2 2023 Portfolio in Review
As of Q2 2023, China Universal Asset Management Company held 465 positions worth $324M, up 9.6% from $295M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
China Universal Asset Management Company's Q2 2023 filing shows 18 new, 159 increased, 243 reduced and 13 closed positions. Its largest new stake was Vanguard World Funds Extended Duration ETF: 37,709 shares worth $3.28M. The largest sale was iQIYI, an estimated $5.11M.
By sector, the portfolio is most concentrated in Technology at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- China Universal Asset Management Company's largest Q2 2023 buy was Vanguard World Funds Extended Duration ETF: 37,709 shares worth $3.28M.
- China Universal Asset Management Company added most to Alnylam Pharmaceuticals in Q2 2023, an estimated $1.96M increase.
- China Universal Asset Management Company's biggest Q2 2023 reduction was iQIYI, cutting an estimated $5.11M.
- China Universal Asset Management Company fully exited Block Inc in Q2 2023, selling an estimated $1.35M.
- China Universal Asset Management Company's ten largest holdings make up 33% of its $324M portfolio in Q2 2023.
- China Universal Asset Management Company opened 18 new positions and closed 13 in Q2 2023.
- China Universal Asset Management Company's portfolio value rose 9.6% quarter-over-quarter to $324M.
Based on China Universal Asset Management Company's 13F filing for Q2 2023, filed 28 Jul 2023.